Publikation
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Wissenschaftlicher Artikel/Review - 28.07.2017
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Bereiche
PubMed
DOI
Zitation
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Blood Cancer J 2017; 7
Veröffentlichungsdatum
28.07.2017
eISSN (Online)
2044-5385
Seiten
e589